Targeting K-Ras cancers  by McCormick, Frank & Wang, Man-Tzu
February 2016 Abstracts S9phase I clinical trial of erlotinib and nivolumab in
patients with EGFR mutated tumors has been
completed (10). The regimen was feasible and well
tolerated with promising antitumor activity. A
randomized phase III trials of an EGFR-TKI versus an
EGFR-TKI with an immune checkpoint inhibitor has
been launched. Similar preclinical evidence supports
the evaluations of ALK-TKIs plus an immune
checkpoint inhibitor (8). Phase I testing has begun.
Immunotherapy combinations. Optimizing the immune
system to attack tumors will require exploiting its diverse
components. Employing a dual immune approach with
anti- PD-1 plus an anti- CTLA-4 agents has been suc-
cessful in treating advanced melanoma. In lung cancer
phase III trials of PD-1 and CTLA-4 inhibitors have been
activated based on encouraging phase I data (12).
Meanwhile, early phase trials evaluating immune
checkpoint inhibitors with immune checkpoint agonists,
cytokines, and vaccines are ongoing to determine the
safest and most effective combinations.
Overall we are optimistic that combination regimens
that can harness the immune system together with tumor
directed therapies will lead to improved clinical beneﬁt.
Continued pursuit of optimal combinations will however
require increased insight into the complex interactions
between the tumor, the immune response and pharma-
cological interventions.
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Activating mutations in K-Ras occur frequently in lung
adenocarcinomas, and are mutually exclusive with other
mutations that activate the MAPK pathway, such as
EGF-R and other receptor tyrosine kinases upstream, loss
of neuroﬁbromin, loss of Spred1 and activation of B-Raf.
Neuroﬁbromin and Spred1 form a functional complex
that inactivates Ras by converting Ras.GTP to Ras.GDP.
Neuroﬁbromin has a GAP domain, and Spred1 is essential
for directing neuroﬁbromin to the plasma membrane.
Binding of neuroﬁbromin to Spred1 is regulated by
phosphorylation, so that the level of neuroﬁbromin that
can inactivate Ras is a highly regulated process. While
mutations in EGF-R, K-Ras, neuroﬁbromin, Spred1, B-Raf
and related genes are likely initiating driver mutations,
knock-down of K-Ras in cell lines often has little effect on
cell survival. This is presumed to be because feedback
loops become activated upon K-Ras ablation, keeping
cells viable. In contrast, ablation of K-Ras in pancreatic
cancer cells leads to more profound effects on survival,
for reasons that will be discussed.
Cells transformed by KRAS display a stem-like
phenotype. In contrast, cells transformed by H-Ras do
not. This difference is not related to MAPK or PI3’ kinase
activation, but is due to KRAS 4B’s’ unique ability to bind
calmodulin, and so to inhibit calmodulin-dependent ki-
nase. Low CaM kinase activity initiates a set of tran-
scriptional programs that confer stem-ness. Binding of K-
Ras to calmodulin is prevented by phosphorylation of K-
Ras on serine-181, by an unknown isoform of protein
kinase C. Treatment of mice with agents that activate
PKC disrupts KRAS binding to calmodulin and prevents
initiation and growth of tumor cells in vivo. Part of the
“stem-ness” program initiated by K-Ras involves secre-
tion of the cytokine LIF, an IL-6 family member with a
unique role in maintaining stem-ness. Neutralization of
LIF with a monoclonal antibody, or ablation of LIF
expression using siRNA or CRISPR, reduces stem-ness
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bine. LIF activates a unique set of downstream pathways,
distinct from IL-6 and other members of this family of
cytokines. This pathway may account for K-Ras’ unique
ability to promote stem-ness. The existence of a new
effector pathway speciﬁc for KRAS therefore offers new
opportunities for therapeutic intervention.
Immunomodulatory effects of
radiotherapy: Magical effects of the
healing beam?Arta M. Monjazeb UC Davis Comprehensive
Cancer Center, Sacramento, CAImmunotherapy is changing the management of meta-
static lung cancer. Checkpoint inhibitors have demon-
strated promising response in non-small cell lung cancer
and are emerging as amongst the most efﬁcacious anti-
cancer agents ever discovered. Checkpoint inhibitors are
aimed at reversing mechanisms of T-cell suppression by
blocking signaling through regulatory T-cell co-receptors
(e.g. CTLA-4 or PD-1) or blocking T-cell suppressive
enzymes (e.g. Indolamine 2,3 Dioxgenase (IDO)). These
therapies can achieve durable long-term remissions,
however, most patients fail to respond, and some can
experience signiﬁcant immune-mediated toxicities (1-3).
Combinatorial strategies employing immunotherapy and
standard-of-care therapies may increase the efﬁcacy of
immunotherapy and extend its beneﬁt to a larger
proportion of patients. Little data is available on how
best to achieve this goal.
Radiotherapy (RT) is an ideal candidate for combinatorial
immunotherapy strategies. In addition to debulking tumor
and releasing tumor antigens, RT has well-established
immunomodulatory effects (4). These interdependent and
overlapping effects include increasing homing and effector
function of tumor inﬁltrating lymphocytes (TILs) including
T-cells (5) and natural killer (NK) cells (6), increasing the
diversity of the T-cell response (7), destruction of
immunosuppressive cells in the tumor microenvironment
(8), induction of immunogenic cell death (9,10), increased
dendritic cell (DC) trafﬁcking and presentation of tumor
antigen (11), and upregulation of immunogenic cell surface
receptors (12) and stress ligands (6). Additionally our
recent data demonstrate that RT can induce chemokines
such as CCL3, 4, and 5 and the critical nature of these
chemokines to an anti-tumor immune response and the
effectiveness of checkpoint blockade immunotherapy has
recently been highlighted (13). The immunomodulatory
effects of radiotherapy are complex and some of these
effects can be suppressive such as induction of TGF-beta
(14), accumulation of immunosuppressive cells (15),
upregulation of PD-L1 (16), and upregulation of IDO.Clinical reports conﬁrm the safety and efﬁcacy of multi-
modality strategies employing RT and CpG or IL-2 immu-
notherapy (17,18). There is also data to suggest synergy
between RT and checkpoint inhibition (16,19,20). Dozens
of clinical trials testing such combinatorial strategies are
underway with countless others in preparation, which
will together likely accrue thousands of patients. There is
considerable variability in “standard-of-care” RT regimens
and combinatorial strategies could employ a wide variety
of dose/fractionation regimens, sequencing/timing
regimens, and even RT quality (i.e. photons vs. protons).
There is limited mechanistic data available to guide how
to best combine these modalities (21,22). These variables
can substantially alter the efﬁcacy of combined RT +
immunotherapy strategies. A framework for
appropriately combining these therapies is needed and
will have an immediate impact on patient care. It is
possible that different immunotherapies and different
tumors will behave differently in response to these RT
variables. The mechanistic immune effects of RT and
immunotherapy are complex. Identifying the best
strategies to combine these immune effects will likely be
similarly complex.
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